Most importantly, the outcomes of ongoing Phase 3 trials (HORIZON, OCEAN[a]-Outcomes) will determine whether targeted Lp(a) lowering can alter the natural history of CAVD. This evidence concerns the gene LPA and congenital bilateral aplasia of vas deferens from CFTR mutation.